TCGA-BH-A0EA-01A-11R-A115-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 33
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MBCProject_7544_T2_RNA | — | A | 0.938 |
| 2 | SRR8613732 | — | A | 0.933 |
| 3 | TCGA-HN-A2OB-01A-21R-A27Q-07 | — | A | 0.929 |
| 4 | TCGA-BH-A28O-01A-11R-A22K-07 | — | A | 0.917 |
| 5 | SRR1313091 | — | A | 0.891 |
| 6 | TCGA-A2-A0EW-01A-21R-A115-07 | — | A | 0.886 |
| 7 | MBCProject_0063_T3A_RNA | — | A | 0.883 |
| 8 | 20050037.TNBC | — | C | 0.881 |
| 9 | SRR35579834 | — | A | 0.878 |
| 10 | BSR_05_0025_A4_S57 | — | A | 0.877 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.430 | Inavolisib | — uncovered |
| MYOGENESIS | 0.430 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.430 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.420 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.380 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.360 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.350 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.310 | Inavolisib | — uncovered |
| COAGULATION | 0.270 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.250 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.250 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.210 | Inavolisib | — uncovered |
| HYPOXIA | 0.190 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.160 | Temsirolimus | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.160 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.150 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.130 | Cobimetinib | — uncovered |
| P53_PATHWAY | 0.110 | Idelalisib | — uncovered |